It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Protecting the whole small intestine from radiation-induced intestinal injury during the radiotherapy of abdominal or pelvic solid tumors remains an unmet clinical need. Amifostine is a promising selective radioprotector for normal tissues. However, its oral application in intestinal radioprotection remains challenging. Herein, we use microalga Spirulina platensis as a microcarrier of Amifostine to construct an oral delivery system. The system shows comprehensive drug accumulation and effective radioprotection in the whole small intestine that is significantly superior to free drug and its enteric capsule, preventing the radiation-induced intestine injury and prolonging the survival without influencing the tumor regression. It also shows benefits on the gut microbiota homeostasis and long-term safety. Based on a readily available natural microcarrier, this work presents a convenient oral delivery system to achieve effective radioprotection for the whole small intestine, providing a competitive strategy with great clinical translation potential.
Protecting the whole small intestine from radiation-induced intestinal injury during the radiotherapy of abdominal or pelvic solid tumors remains an unmet clinical need. Here the authors use a natural microalga to readily construct an oral delivery system to achieve effective radioprotection for the small intestine.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Tao, Wei 2
; Zhou, Min 5
1 Zhejiang University School of Medicine, Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Yiwu, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, Institute of Translational Medicine, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
2 Harvard Medical School, Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Zhejiang University, Institute of Translational Medicine, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
4 Harvard University, School of Engineering and Applied Sciences, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts Institute of Technology, School of Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
5 Zhejiang University School of Medicine, Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Yiwu, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, Institute of Translational Medicine, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, State Key Laboratory of Modern Optical Instrumentations, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, Cancer Center, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)




